The cell therapy technologies market is projected to reach USD 19.9 billion by 2023 from USD 10.2 billion in 2018, at a CAGR of 14.4%. Factors such as rising government investments for cell-based research, the increasing number of GMP-certified production facilities, and the large number of oncology-oriented cell-based therapy clinical trials are driving the growth of this market.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978Factors such as rising government investments for cell-based research, the increasing number of GMP-certified production facilities, and the large number of oncology-oriented cell-based therapy clinical trials are driving the growth of this market.Global Cell Therapy Technologies Market Segmentation:By product, the cell therapy technologies market is segmented into consumables, equipment, and systems & software. The consumables segment is expected to account for the largest share of the market in 2018. Factors such as increasing investments by companies to develop advanced products as well as government initiatives for enhancing cell-based research are contributing to the growth of the cell therapy consumables market.Based on process, the cell therapy technologies market is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control. The cell processing segment is expected to account for the largest market share in 2018 and is projected to witness the highest CAGR during the forecasted period.Based on cell type, the market is segmented into human cells and animal cells. In 2018, the human cells segment is expected to account for the largest share of the cell therapy technologies market. The rising adoption of human cells over animal cells for cell therapeutics research, technological advancements, and the rising incidence of diseases such as cancer and cardiac abnormalities are the key factors driving the growth of this segment.Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=213334978What Drives the Market?1. Rising Government Investments in Cell-Based Research2. Large Number of Oncology-Oriented Cell-Based Therapy Clinical Trials3. Affordability and Sustainability of Advanced Cell Therapy InstrumentsGeographical Growth Analysis:The market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to dominate the market in 2018 owing to the high burden of chronic diseases and increasing R&D activities in the pharmaceutical and biotechnology industries. The Asia Pacific region is expected to register the highest CAGR during the forecast period. The increasing demand for cell therapy instruments and products from China, India, and Japan primarily due to the increasing research funding for vaccine development and changing disease profiles is supporting the growth of the market in the Asia Pacific.Key Players and Strategies Adopted by Them:Key players in this cell therapy technologies market include Beckman Coulter (US), Becton, Dickinson and Company (US), GE Healthcare (US), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT (US), and Thermo Fisher Scientific (US).Speak to Analyst @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=213334978
The high incidence of cancer and other target diseases, availability of reimbursement, and the growing focus on personalized medicine are the major factors driving the growth of the anatomic pathology market.According to the new market research report " anatomic pathology market by Product & Service (Instruments (Tissue Processing Systems, Microtome), Consumables (Reagent & Antibodies), Histopathology, Cytopathology), Application (Disease Diagnosis, Drug Discovery & Development) - Forecasts to 2021", published by MarketsandMarkets™, The anatomic pathology market was valued at USD 16.2 Billion in 2016 and poised to grow at a CAGR of 6.1% between 2016 and 2021, to reach USD 21.9 Billion in 2021.Download PDF Brochure :https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145Market segmented into :1. By product & service, the market is segmented into services, instruments, and consumables. The services segment accounted for the largest market share in 2018 and is expected to register the highest CAGR during the forecast period. The growth of this segment can be attributed to the availability of reimbursements for diagnostic tests, rapid growth in the geriatric population, and the increasing incidence of cancer and other chronic diseases.2. Based on application, the market is segmented into disease diagnosis and medical research. The market for disease diagnosis is further segmented into cancer and other diseases. In 2018, the disease diagnosis segment accounted for the largest market share. This can be attributed to the rapid growth in the geriatric population and the increasing incidence of cancer and other chronic diseases.3. Based on region, the market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest market share, followed by Europe. The easy accessibility to advanced technologies, government initiatives for screening cancer patients, favorable reimbursement scenario for anatomic pathology diagnostic tests, increasing healthcare expenditure, and the presence of high-quality infrastructure for hospitals and clinical laboratories in the region are the major factors driving the growth of the market in North America.Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145
Geographical Growth Analysis:Based on region, the market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest market share, followed by Europe. The easy accessibility to advanced technologies, government initiatives for screening cancer patients, favorable reimbursement scenario for anatomic pathology diagnostic tests, increasing healthcare expenditure, and the presence of high-quality infrastructure for hospitals and clinical laboratories in the region are the major factors driving the growth of the market in North America.Some of The Major Players In Anatomic Pathology Market:Prominent players in the anatomic pathology market include F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific (US), Hologic, Inc. (US), Agilent Technologies (US), Becton, Dickinson and Company (US), Sakura Finetek (Japan), Merck KGaA (Germany), Bio SB (US), Diapath S.p.A. (Italy), and BioGenex Laboratories (US).
The China cardiology information system market is projected to reach $54 million by 2024 from $35 million in 2019, at a CAGR of 8.9% during the forecast period. Growth in this market is mainly driven by the increasing incidence and prevalence of cardiovascular disease, government initiatives in China, and the increasing number of hospitals.Integrated systems accounted for the largest share of the China cardiology information system market in 2018On the basis of system, the China cardiology information system market is segmented into integrated and standalone systems. In 2018, integrated systems accounted for the largest share of the China cardiology market. The large share of this segment can be attributed to the increasing adoption of these systems by healthcare providers and the increasing incidence & prevalence of cardiovascular diseases.Download PDF Brochure@https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=264168583
By component, the software segment accounted for the largest market share in 2018On the basis of component, the China cardiology information system market is segmented into software, hardware, and service. The software segment accounted for the largest market share in 2018. This is attributed to the rising number of hospitals and the consequent increase in the demand for CVIS and CPACS, among other technologies.L3A Hospitals are the largest end users in the China cardiology information system marketBased on end user, the China cardiology information system market is segmented into L3A, L3B, and L2 hospitals. The L3A hospitals segment accounted for the largest market share in 2018. The increasing number of L3A hospitals and the rising incidence of cardiovascular diseases in China are the major market drivers for this segment.The key players in the China cardiology information system market are Philips Healthcare (Netherlands), CREALIFE Medical Technology (China), Central Data Network (Australia), Infinitt Healthcare (South Korea), and Esaote (Italy).Read More@https://www.marketsandmarkets.com/PressReleases/cardiology-information-system.asp
The high incidence of cancer and other target diseases, availability of reimbursement, and the growing focus on personalized medicine are the major factors driving the growth of the anatomic pathology market.The services segment accounted for the largest share of the anatomic pathology market, by product & service, in 2018Based on product & service, the anatomic pathology market is segmented into services, consumables, and instruments. The services segment accounted for the largest share of the anatomic pathology market in 2018. The large share of this segment can be attributed to the availability of reimbursements for diagnostic tests, rapid growth in the geriatric population, and the increasing incidence of cancer and other chronic diseases.Download PDF Brochure@https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145
Hospital laboratories segment to register the highest growth rate during the forecast periodBased on end user, the anatomic pathology market is segmented into hospital laboratories, clinical laboratories, and other end users. In 2018, the hospital laboratories segment accounted for the largest market share and is expected to grow at the highest CAGR during the forecast period. The growth in this market can be attributed to the increasing number of patient visits to hospitals, growing number of in-house diagnostic procedures performed in hospitals, growing awareness regarding early disease diagnosis, and the availability of reimbursements in developed markets for clinical tests performed in hospitals.North America is the largest regional market for anatomic pathologyBy region, the anatomic pathology market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America accounted for the largest market share, followed by Europe. The rising prevalence of chronic diseases, increasing healthcare expenditure, the high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the anatomic pathology market in North America.The prominent players operating in the anatomic pathology market include F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific (US), Hologic, Inc. (US), Agilent Technologies (US), Becton, Dickinson and Company (US), Sakura Finetek (Japan), Merck KGaA (Germany), Bio SB (US), Diapath S.p.A. (Italy), and BioGenex Laboratories (US).Request Sample Pages@https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145
The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.According to the new market research report " Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", published by MarketsandMarkets™, The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724
The digital therapeutics market is highly fragmented, diversified, and increasingly competitive, with a large number of small players competing for market space, including startup firms.Global Market Segmentation:Each segment has different market players and market leaders. For instance, the prediabetes market was led by Omada in 2015. Omada Health is a leading provider of digital therapeutics for preventable type 2 diabetes and heart disease. Omada’s product portfolio consists of ‘Prevent’, an online diabetes prevention program. The company has succeeded in securing heavy investments which it channelizes into the development, enhancement, and commercialization of its product.Based on sales channel, the digital therapeutics market is segmented into business to customer (B2C) and business to business (B2B). In 2016, the B2B segment is estimated to account for the largest share along with the highest CAGR of the digital therapeutics market. There is a growing awareness among providers, payers, and employers about the benefits provided by digital therapeutics, and the amount of healthcare cost reductions achieved by their use.Additionally, there is a growing inclination of pharmaceutical companies to integrate digital therapeutics with their drug product to offer adherence services along with their product. These are some of the factors responsible for the high share of this market segment.Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724What Drives the Market?1. Increasing Incidence of Preventable Chronic Diseases2. Rising Focus on Preventive Healthcare3. Technological Advancements4. Need to Control Healthcare Costs5. Significant Increase in Venture Capital Investments6. Benefits Offered By Digital TherapeuticsGeographical Growth Analysis:The digital therapeutics market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). In 2016, the North America is expected to dominate the market, followed by Europe. The market in North America is expected to grow at the highest CAGR during the forecast period.Key Players and Strategies Adopted by Them:Proteus Digital Health, Inc. (U.S.), Omada Health Inc. (U.S.), WellDoc Inc. (U.S.), Livongo Health (U.S.), Noom Inc. (U.S.), Ginger.io Inc. (U.S.), Propeller Health (U.S.), 2Morrow Inc. (U.S.), Canary Health Inc. (U.S.), Mango Health, Inc. (U.S.), and Physitrack Limited (U.K.). Click Therapeutics, Inc. (U.S.), Pear Therapeutics, Inc., (U.S.), Akili Interactive Labs, Inc. (U.S.) and Wellthy Therapeutics Pvt. Ltd (India)Speak to Analyst @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=51646724
The health information exchange market is projected to reach USD 1,545.0 million by 2020 from USD 990.6 million in 2015, at a CAGR of 9.3% during the forecast period. Federal mandates like Meaningful use, growing patient-centric approach in healthcare delivery, increasing EHR adoption rate, and need to curtail healthcare cost are some of the key factors driving the growth of market.Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249987292Health information exchange (HIE) involves the electronic movement of health-related information among organizations according to nationally recognized standards. HIE aims to facilitate the access and retrieval of clinical data to provide safer, timelier, efficient, effective, equitable, patient -centered care. HIE enables collaboration between healthcare stakeholders, cuts down on administrative tasks, and eventually provides greater transparency in the field of healthcare. HIE is an ever-changing concept. Continuously changing technological and regulatory environment consistently evolves the HIE space.Global Health Information Exchange Market Segmentation:The health information exchange market has been segmented, on the basis of type, into directed exchange, query-based exchange, and consumer-mediated exchange. The directed exchange segment accounted for the largest share of the global market in 2015. Directed exchange supports point-to-point transactions and transmits documents to physicians’ EHR; this is contributing to the large share of this segment.Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249987292What Drives the Market?
1. Strong Government Support and Initiatives2. Increased Measures to Improve Healthcare Quality and Care Coordination Likely to Trigger HIE Adoption3. Need to Curtail Healthcare CostsGeographical Growth Analysis:The health information exchange market in Asia-Pacific is expected to grow at the fastest rate during the forecast period. High growth in this regional segment can primarily be attributed to the growing initiatives for Japan’s EHR adoption and ICT fund, investments and reforms to modernize China’s healthcare infrastructure, rapidly growing Indian healthcare industry, implementation of HCIT programs in Australia & New Zealand, and One Singaporean One Health Record - one of the pioneer patient management programs in Singapore.Key Players and Strategies Adopted by Them:Key players in Health Information Exchange Market include Allscripts Healthcare Solutions, Inc. (U.S.), Relayhealth Corporation (U.S.), Infor, Inc. (U.S.), Cerner Corporation (U.S.), and eClinicalWorks (U.S.) among others. These players are increasingly undertaking mergers and acquisitions, and product launches to develop and introduce new technologies and products in the market.Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=249987292
The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, the launch of new and advanced NIPT products, and increasing maternal age (growth in the risk of chromosomal abnormalities in babies).
Please share your specific interest to serve you better, Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690
What the Market Looks Like?
Predicted to grow at a CAGR of 13.5% during the forecast period,the global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019. The global Non Invasive Prenatal Testing (NIPT)Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.
> By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period.
> Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type).
> Based on end user, the NIPT products market is classified into diagnostic laboratories and hospitals. In 2019, diagnostic laboratories formed the largest and fastest-growing end users of NIPT products.
Get Sample Copy of This Report
@https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690
What Drives the Market?
The growth of the global market for Non Invasive Prenatal Testing (NIPT) is primarily influenced by the following factors:
• High Risk of Chromosomal Abnormalities With Increasing Maternal Age
• Growing Preference for Noninvasive Techniques Over Invasive Methods
• Improving Reimbursement Scenario for NIPT
• Programs Focusing on Increasing the Awareness of NIPT
Untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period. On the other hand, a dearth of skilled professionals is expected to restrain the growth of this market in the coming years.
Geographical growth scenario of Non Invasive Prenatal Testing (NIPT) :
Geographically, Non Invasive Prenatal Testing (NIPT) market has been studied for North America dominated the market, followed by Europe. The large share of this market can primarily be attributed to the strong economies in the US and Canada, which have allowed for significant investments in technology in this region.
Leading market players and strategies adopted
The NIPT market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)
Read More: https://www.marketsandmarkets.com/PressReleases/non-invasive-prenatal-testing.asp
